Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.43.6 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.43.6 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBF.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBF.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.4NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.27NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.27NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.43.9 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.43.9 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.43.9 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XUNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XUNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XUNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.3 (Omicron)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.3 (Omicron)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.3 (Omicron)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.3.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.3.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.1.16.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.16.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.16.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.372NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.372NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.372NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
C.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.8NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.425NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.425NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.425NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.5.55NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.55NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.55NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
HH.8.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HH.8.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
HH.8.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FL.19NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.19NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.19NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FM.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FM.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FM.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FK.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FK.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FK.1.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.2.7.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.2.7.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.2.7.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used